https://mindmedicinelaw.com/briefing/rhelion-life-sciences-psilocybin-supply-deal-with-uw-20260825-35453The Psychedelic Journalen2026-08-25T15:05:43.217830+00:00Rhelion Life Sciences' Psilocybin Supply Deal with UWpsilocybin research, Rhelion Life Sciences, University of Washington, clinical trials, psychedelic therapies, mental health treatment, regulatory implications, biotech partnershipshttps://mindmedicinelaw.com/briefing/oregon-s-psychedelic-dataset-outpaces-historical-trials-20260825-35452The Psychedelic Journalen2026-08-25T15:04:44.499541+00:00Oregon's Psychedelic Dataset Outpaces Historical TrialsOregon psychedelic dataset, state-level data, federal regulators, psilocybin therapy, clinical trials, policy implications, data integration, psychedelic research, public health, therapeutic applicationshttps://mindmedicinelaw.com/briefing/bmi-s-influence-on-depression-treatment-outcomes-20260824-35383The Psychedelic Journalen2026-08-25T15:05:58.306201+00:00BMI's Influence on Depression Treatment OutcomesBMI, treatment-resistant depression, systematic review, personalized medicine, pharmacotherapy, ketamine, transcranial magnetic stimulationhttps://mindmedicinelaw.com/briefing/cmps-stock-surge-implications-for-fda-psychedelic-review-20260824-35451The Psychedelic Journalen2026-08-25T15:05:25.320258+00:00CMPS Stock Surge: Implications for FDA Psychedelic ReviewCMPS stock, FDA hearing, psychedelic therapies, regulatory pathways, market dynamics, drug approval process, psilocybin research, investor confidence, mental health treatment, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-opioid-nature-implications-for-regulation-and-therapy-20260824-35444The Psychedelic Journalen2026-08-25T15:04:58.010610+00:00Ketamine's Opioid Nature: Implications for Regulation and Therapyketamine, opioid receptors, pharmacodynamics, mental health treatment, regulatory classification, clinical guidelineshttps://mindmedicinelaw.com/briefing/psilocybin-regulation-and-use-in-oregon-current-status-20260824-35337The Psychedelic Journalen2026-08-24T22:04:11.149360+00:00Psilocybin Regulation and Use in Oregon: Current Statuspsilocybin legalization, Oregon psilocybin regulation, psychedelic therapy, psilocybin policy, therapeutic psilocybin, psilocybin community impact, psilocybin research, psilocybin risks, psilocybin integration services, Oregon Health Authorityhttps://mindmedicinelaw.com/briefing/psilocybin-s-clinical-viability-faces-critical-challenges-20260824-35182The Psychedelic Journalen2026-08-24T15:05:18.251321+00:00Psilocybin's Clinical Viability Faces Critical Challengespsilocybin clinical trials, psychedelic therapy, mental health treatment, FDA regulations, serotonin receptors, psychedelic industry, therapeutic potential, clinical efficacy, regulatory challenges, psilocybin riskshttps://mindmedicinelaw.com/briefing/mdma-n-acylethanolamines-patent-implications-for-ptsd-treatment-20260824-35183The Psychedelic Journalen2026-08-24T15:05:05.828975+00:00MDMA-N-Acylethanolamines Patent: Implications for PTSD TreatmentMDMA-N-Acylethanolamines, PTSD treatment, psychedelic therapies, patent application, clinical trials, psychedelic industryhttps://mindmedicinelaw.com/briefing/neurothera-clearmind-s-mdma-ptsd-treatment-ip-gains-momentum-20260824-35181The Psychedelic Journalen2026-08-24T15:04:14.893965+00:00NeuroThera-Clearmind's MDMA-PTSD Treatment IP Gains MomentumMDMA, PTSD treatment, NeuroThera, Clearmind, psychedelic research, federal support, clinical trials, N-acylethanolamines, psychedelic therapies, market dynamicshttps://mindmedicinelaw.com/briefing/trait-responsiveness-and-placebo-effects-in-psychedelic-trials-20260823-35370The Psychedelic Journalen2026-08-25T15:06:09.365278+00:00Trait Responsiveness and Placebo Effects in Psychedelic Trialstrait responsiveness, placebo effects, psychedelic research, clinical trials, verbal suggestions, meta-analysishttps://mindmedicinelaw.com/briefing/missouri-s-first-ketamine-clinic-a-new-era-in-psychedelic-therapy-20260823-35067The Psychedelic Journalen2026-08-23T22:03:49.668329+00:00Missouri's First Ketamine Clinic: A New Era in Psychedelic Therapyketamine therapy, psychedelic treatments, Missouri clinic, mental health, psychedelic-assisted therapy, NMDA receptors, depression treatment, PTSD therapy, psychedelic research, ketamine clinichttps://mindmedicinelaw.com/briefing/triptally-analyzing-psychedelic-therapy-costs-with-open-access-tool-20260821-35103The Psychedelic Journalen2026-08-24T15:04:28.346038+00:00TripTally: Analyzing Psychedelic Therapy Costs with Open-Access Toolpsychedelic therapy, TripTally, cost calculator, economic modeling, labor costs, FDA approval, healthcare integration, therapy delivery models, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/reevaluating-psychedelic-trial-designs-challenges-and-solutions-20260820-35106The Psychedelic Journalen2026-08-24T15:04:41.418953+00:00Reevaluating Psychedelic Trial Designs: Challenges and Solutionspsychedelic trials, clinical trial design, pretreatment expectancy, double-blind procedure, causal identification, alternative trial designs, psychedelic therapy, research methodology, ethical considerationshttps://mindmedicinelaw.com/briefing/oregon-psilocybin-services-show-long-term-benefits-20260819-35454The Psychedelic Journalen2026-08-25T15:05:11.526441+00:00Oregon Psilocybin Services Show Long-Term Benefitspsilocybin therapy, Oregon psilocybin services, mental health treatment, psychedelic research, public health policy, clinical trials, long-term benefits, serotonin receptors, psychedelic therapy, mental health outcomeshttps://mindmedicinelaw.com/briefing/inflammation-s-role-in-depression-insights-challenges-20260819-34857The Psychedelic Journalen2026-08-23T22:04:16.034060+00:00Inflammation's Role in Depression: Insights & Challengesinflammation, major depressive disorder, CRP levels, precision medicine, biomarker stratification, anti-inflammatory treatments, clinical trials, neurotransmission, blood-brain barrier, neuroplasticityhttps://mindmedicinelaw.com/briefing/challenges-in-ehr-based-risk-models-for-trd-across-health-systems-20260819-34547The Psychedelic Journalen2026-08-23T22:04:07.862572+00:00Challenges in EHR-Based Risk Models for TRD Across Health Systemstreatment-resistant depression, electronic health records, risk models, transportability, clinical heterogeneity, data biases, health systems, predictive modeling, EHR limitations, TRDhttps://mindmedicinelaw.com/briefing/advances-in-rtms-for-psychiatric-disorders-challenges-and-future-directions-20260819-34548The Psychedelic Journalen2026-08-23T22:03:59.926146+00:00Advances in rTMS for Psychiatric Disorders: Challenges and Future Directionsrepetitive transcranial magnetic stimulation, psychiatric disorders, clinical efficacy, standardized parameters, biomarkers, multicenter trials, neuro-navigation, personalized treatment, brain stimulation, mental healthhttps://mindmedicinelaw.com/briefing/psilocybin-use-in-older-adults-new-insights-and-implications-20260818-35075The Psychedelic Journalen2026-08-24T15:04:54.082654+00:00Psilocybin Use in Older Adults: New Insights and Implicationspsilocybin, older adults, psychedelic research, state-regulated services, mental health, end-of-life care, clinical trials, therapeutic interventions, safety, efficacyhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-post-op-pain-in-gynecological-surgery-20260818-34864The Psychedelic Journalen2026-08-23T22:04:26.271229+00:00Ketamine and Esketamine for Post-Op Pain in Gynecological Surgeryketamine, esketamine, postoperative pain, gynecological surgery, opioid alternatives, perioperative analgesia, Cochrane review, pain management, clinical trials, subanaesthetic doseshttps://mindmedicinelaw.com/briefing/fanon-s-insights-on-psychedelics-for-racialized-therapy-20260815-34495The Psychedelic Journalen2026-08-23T22:04:35.007223+00:00Fanon's Insights on Psychedelics for Racialized Therapypsychedelic therapy, Frantz Fanon, racialized individuals, anti-colonial frameworks, systemic racism, MDMA-assisted therapy, cultural sensitivity, equitable treatment, psychedelic research, colonial traumahttps://mindmedicinelaw.com/briefing/psychologists-personal-mdma-use-influences-therapy-attitudes-20260813-34514The Psychedelic Journalen2026-08-23T22:04:43.925600+00:00Psychologists' Personal MDMA Use Influences Therapy AttitudesMDMA-assisted therapy, psychologists' attitudes, personal MDMA use, evidence-based education, mental health treatment, therapeutic biases, MDMA-AT risks, clinical objectivity, therapeutic integration, healthcare professional training